CN112007119A - Traditional Chinese medicine composition for treating carotid arteriosclerosis and application thereof - Google Patents
Traditional Chinese medicine composition for treating carotid arteriosclerosis and application thereof Download PDFInfo
- Publication number
- CN112007119A CN112007119A CN202011097703.2A CN202011097703A CN112007119A CN 112007119 A CN112007119 A CN 112007119A CN 202011097703 A CN202011097703 A CN 202011097703A CN 112007119 A CN112007119 A CN 112007119A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating carotid arteriosclerosis and application thereof, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 6-15 parts of rhizoma cyperi, 6-15 parts of ligusticum wallichii, 6-15 parts of rhizoma atractylodis, 6-15 parts of gardenia jasminoides, 6-15 parts of medicated leaven, 6-15 parts of hawthorn and 10-45 parts of corn stigma. Its advantages are: (1) the raw materials and the weight part ratio thereof are optimized, the compatibility of monarch, minister, assistant and guide is met among the medicines in the formula, the medicines are combined, and the effect of relieving six-depression is achieved. (2) The traditional Chinese medicine composition can be prepared into various clinically acceptable dosage forms according to a conventional preparation method of medicines, the preparation method is simple, the sources of the raw materials are wide, the economic burden of patients is greatly reduced, and the traditional Chinese medicine composition has strong practicability and wide clinical application prospect.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating carotid arteriosclerosis and application thereof.
Background
Carotid atherosclerosis, which is the manifestation of systemic atherosclerosis in the carotid artery, is currently considered to be closely related to the occurrence of ischemic stroke in the elderly. The carotid arteriosclerosis is firstly shown as intima-media thickening in the early stage, then an atherosclerotic plaque is gradually formed, and then, the plaque internal hemorrhage, plaque rupture and detachment, mural thrombosis, secondary vessel stenosis and the like are caused on the basis, so that the corresponding hemodynamics is changed, and the occurrence of ischemic cerebrovascular events is caused.
The carotid atherosclerotic plaque is a part of systemic Atherosclerosis (AS), and the lesion degree of the carotid atherosclerosis can be observed more accurately through the detection of the modern medical imaging technology and is regarded AS a window reflecting the lesion of the systemic AS. Carotid atherosclerosis often exists with coronary artery vessels, cerebral artery vessels and the like, and the degree of pathological changes is directly related to the occurrence of cerebrovascular diseases. Early reduction and reversion of atherosclerotic plaque of carotid artery can reduce the occurrence of cerebral apoplexy.
Traditionally, arteriosclerosis is considered to belong to the category of 'blood stasis'. The theory of traditional Chinese medicine considers that the syndrome of qi deficiency and blood stasis is the main pathological basis of the senile diseases and is closely related to immune dysfunction and prothrombotic state. Deficiency of qi, blood and body fluids is common in old age and weak health. The constitution of the elderly patients is mostly due to deficiency of five internal organs, which is caused by qi deficiency and kidney deficiency, and blood flows in vessels constantly. Depending on the promotion of qi, the so-called "qi is the commander of blood" and "qi moving is the blood moving". Qi deficiency fails to promote blood circulation in vessels, and makes the blood flow weaker, slow or stagnant, leading to blood stasis. The basic pathogenesis of the chronic bronchitis is deficiency of both qi and yin and qi deficiency and blood stasis. Hemorheology has been recognized as one of the objective indicators of blood stasis syndrome. Patients with qi deficiency and blood stasis have poor qi and blood fluidity, the hemorheology indexes such as whole blood viscosity and plasma viscosity are increased, the red blood cell electrophoresis time is prolonged, and the red blood cell aggregation index is increased.
The method for treating the carotid atherosclerotic plaque by western medicine comprises traditional Chinese medicine treatment and non-traditional Chinese medicine treatment. Non-traditional Chinese medicine treatments include carotid endarterectomy, carotid stenting angioplasty, and optical chemistry carotid angioplasty, but are difficult, expensive, and traumatic. The traditional Chinese medicine treatment mainly aims at regulating lipid, resisting blood platelet and resisting oxidation, but the clinical effect is not satisfactory.
Aiming at the defects in the prior art, the invention provides a traditional Chinese medicine composition for treating carotid arteriosclerosis and application thereof, and the invention is not reported at present.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating carotid arteriosclerosis and application thereof aiming at the defects of the prior art.
In order to achieve the purpose, the invention adopts the technical scheme that:
on one hand, the invention provides a traditional Chinese medicine composition for treating carotid arteriosclerosis, which comprises the following raw material medicines in parts by weight: 6-15 parts of rhizoma cyperi, 6-15 parts of ligusticum wallichii, 6-15 parts of rhizoma atractylodis, 6-15 parts of gardenia jasminoides, 6-15 parts of medicated leaven, 6-15 parts of hawthorn and 10-45 parts of corn stigma.
Preferably, the traditional Chinese medicine composition consists of the following raw material medicines in parts by weight: 8-10 parts of rhizoma cyperi, 8-10 parts of ligusticum wallichii, 8-10 parts of rhizoma atractylodis, 8-10 parts of gardenia jasminoides, 8-10 parts of medicated leaven, 8-10 parts of hawthorn and 20-40 parts of corn stigma.
Preferably, the traditional Chinese medicine composition consists of the following raw material medicines in parts by weight: 9 parts of rhizoma cyperi, 9 parts of ligusticum wallichii, 9 parts of rhizoma atractylodis, 9 parts of gardenia jasminoides, 9 parts of medicated leaven, 9 parts of hawthorn and 30 parts of corn stigma.
Further, the traditional Chinese medicine composition is prepared into a clinically acceptable pharmaceutical preparation according to a conventional traditional Chinese medicine preparation method.
Preferably, the pharmaceutical preparation is granules, powder, capsules, tablets, mixture or oral liquid.
On the other hand, the invention also provides application of the traditional Chinese medicine composition in preparing a medicine for treating carotid arteriosclerosis.
Preferably, the invention provides application of the traditional Chinese medicine composition in preparing a medicine for treating carotid arteriosclerosis with syndrome of intermingled phlegm and blood stasis.
Furthermore, the invention provides a medicine for treating carotid arteriosclerosis, which is prepared by decocting the traditional Chinese medicine composition with water.
Preferably, the preparation method of the medicament comprises the following steps:
(1) taking raw material medicines: rhizoma Cyperi, rhizoma Ligustici Chuanxiong, rhizoma Atractylodis, fructus Gardeniae, Massa Medicata Fermentata, fructus crataegi, and stigma Maydis, decocting with water over strong fire for 0.5-1.5 hr;
(2) decocting with slow fire for 20-40 min;
(3) and (4) leaching out juice, precipitating, taking clear liquid, and bottling for later use.
Square solution:
in the formula, the nutgrass galingale rhizome, pungent and fragrant, enters the liver to promote the circulation of qi and relieve depression so as to treat qi depression; the rhizoma ligustici wallichii is pungent and warm in property and enters liver and gallbladder, is a blood-qi-activating medicine, and can activate blood, remove stasis, treat blood stagnation and help the rhizoma cyperi to promote qi circulation and relieve depression; cape jasmine is bitter and cold in taste, clears heat and purges fire to treat fire stagnation; rhizoma Atractylodis is pungent and bitter with warm property, and can dry dampness and activate spleen to treat damp stagnation; the medicated leaven is sweet in flavor and warm in nature, and can promote digestion and remove food stagnation to treat food stagnation, and the medicated leaven are monarch drugs; the hawthorn is sour, sweet and warm, has the effects of promoting qi circulation, removing blood stasis, eliminating turbid pathogen and reducing blood fat, can also help the medicated leaven to promote digestion and invigorate stomach, and is used as a ministerial drug; corn stigma is sweet and mild in nature, and has the effects of removing dampness by diuresis and promoting diuresis, and is used as an adjuvant drug. The medicines are combined to play the role of 'relieving six depression' together.
The invention has the advantages that:
1. aiming at the causes and pathogenesis of carotid arteriosclerosis, the raw materials and the weight part ratio thereof are preferably selected, the compatibility of monarch, minister, assistant and guide is met among the medicines in the formula, the medicines are combined, the effect of relieving six-depression is achieved, and the curative effect is good.
2. The raw material medicines have wide sources, the preparation method of the medicine is simple and convenient, the medicine can be prepared into clinically acceptable dosage forms according to the needs, the comfort level of patients is improved, the economic burden of the patients is greatly reduced, the practicability is high, and the application prospect is wide.
Drawings
FIG. 1 shows the integral comparison of the syndrome of traditional Chinese medicine before and after treatment.
FIG. 2 shows the comparison of the therapeutic effects of Chinese herbs before and after treatment.
Detailed Description
The invention will be further illustrated with reference to specific embodiments. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Furthermore, it should be understood that various changes and modifications can be made by those skilled in the art after reading the disclosure of the present invention, and equivalents fall within the scope of the appended claims.
EXAMPLE 1 Chinese medicinal composition 1
Taking the following raw material medicines according to the following weight parts: 6 parts of rhizoma cyperi, 6 parts of ligusticum wallichii, 6 parts of rhizoma atractylodis, 6 parts of gardenia jasminoides, 6 parts of medicated leaven, 6 parts of hawthorn and 10 parts of corn stigma.
EXAMPLE 2 Chinese medicinal composition (II)
Taking the following raw material medicines according to the following weight parts: 15 parts of rhizoma cyperi, 15 parts of ligusticum wallichii, 15 parts of rhizoma atractylodis, 15 parts of gardenia jasminoides, 15 parts of medicated leaven, 15 parts of hawthorn and 45 parts of corn stigma.
EXAMPLE 3 Chinese medicinal composition (III)
Taking the following raw material medicines according to the following weight parts: 6 parts of rhizoma cyperi, 15 parts of ligusticum wallichii, 6 parts of rhizoma atractylodis, 15 parts of gardenia jasminoides, 6 parts of medicated leaven, 15 parts of hawthorn and 10 parts of corn stigma.
EXAMPLE 4 Chinese medicinal composition (IV)
Taking the following raw material medicines according to the following weight parts: 15 parts of rhizoma cyperi, 6 parts of ligusticum wallichii, 15 parts of rhizoma atractylodis, 6 parts of gardenia jasminoides, 15 parts of medicated leaven, 6 parts of hawthorn and 45 parts of corn stigma.
EXAMPLE 5 Chinese medicinal composition (V)
Taking the following raw material medicines according to the following weight parts: 8 parts of rhizoma cyperi, 8 parts of ligusticum wallichii, 8 parts of rhizoma atractylodis, 8 parts of gardenia jasminoides, 8 parts of medicated leaven, 8 parts of hawthorn and 20 parts of corn stigma.
EXAMPLE 6 Chinese medicinal composition (VI)
Taking the following raw material medicines according to the following weight parts: 10 parts of rhizoma cyperi, 10 parts of ligusticum wallichii, 10 parts of rhizoma atractylodis, 10 parts of gardenia jasminoides, 10 parts of medicated leaven, 10 parts of hawthorn and 40 parts of corn stigma.
EXAMPLE 7 Chinese medicinal composition (seven)
Taking the following raw material medicines according to the following weight parts: 8 parts of rhizoma cyperi, 10 parts of ligusticum wallichii, 8 parts of rhizoma atractylodis, 10 parts of gardenia jasminoides, 8 parts of medicated leaven, 10 parts of hawthorn and 20 parts of corn stigma.
EXAMPLE 8 Chinese medicinal composition (eight)
Taking the following raw material medicines according to the following weight parts: 10 parts of rhizoma cyperi, 8 parts of ligusticum wallichii, 10 parts of rhizoma atractylodis, 8 parts of gardenia, 10 parts of medicated leaven, 8 parts of hawthorn and 40 parts of corn stigma.
EXAMPLE 9 Chinese medicinal composition (nine)
Taking the following raw material medicines according to the following weight parts: 9 parts of rhizoma cyperi, 9 parts of ligusticum wallichii, 9 parts of rhizoma atractylodis, 9 parts of gardenia jasminoides, 9 parts of medicated leaven, 9 parts of hawthorn and 30 parts of corn stigma.
Example 10 granules
The preparation method comprises the following steps: the raw materials are taken according to the weight parts of the embodiments 1-9 respectively: rhizoma Cyperi, rhizoma Ligustici Chuanxiong, rhizoma Atractylodis, fructus Gardeniae, Massa Medicata Fermentata, fructus crataegi, and stigma Maydis, decocting with water over strong fire for 0.5-1.5 hr; then decocting with slow fire for 20-40 minutes; draining juice, precipitating, collecting supernatant, concentrating into fluid extract, and making into granule.
EXAMPLE 11 tablet/Capsule
The preparation method comprises the following steps: the raw materials are taken according to the weight parts of the embodiments 1-9 respectively: rhizoma Cyperi, rhizoma Ligustici Chuanxiong, rhizoma Atractylodis, fructus Gardeniae, Massa Medicata Fermentata, fructus crataegi, and stigma Maydis, decocting with water over strong fire for 0.5-1.5 hr; then decocting with slow fire for 20-40 minutes; leaching to obtain juice, precipitating, concentrating the supernatant to obtain soft extract, adding pharmaceutical adjuvants, vacuum drying, pulverizing, granulating, and making into tablet or capsule.
Example 12 decoction
The preparation method comprises the following steps: the raw materials are taken according to the weight parts of the embodiments 1-9 respectively: rhizoma Cyperi, rhizoma Ligustici Chuanxiong, rhizoma Atractylodis, fructus Gardeniae, Massa Medicata Fermentata, fructus crataegi, and stigma Maydis, decocting with water over strong fire for 0.5-1.5 hr; decocting with slow fire for 20-40 min, filtering to remove residue, and collecting supernatant.
EXAMPLE 13 clinical trial
1 data of
1.1 study object
The selected cases are outpatients and inpatients of home cardiology department in 4 months to 12 months in 2019, the age is 18-75 years, western medicine accords with carotid arteriosclerosis diagnosis, and traditional Chinese medicine accords with phlegm-blood stasis syndrome diagnosis.
1.2 diagnostic criteria
1.2.1 diagnostic criteria for carotid arteriosclerosis
Referring to the sixth edition of ultrasonic medicine, which is the main edition of 2011 edition of Guo Wan school, the obvious arteriosclerosis is represented by thickening of intima-media thickness (IMT), and the IMT is more than or equal to 1.0mm (the bifurcation is more than or equal to 1.2mm) for thickening; if the local IMT thickness is greater than or equal to 1.5mm, plaque formation can be diagnosed. According to the plaque property, if the strong echo or the shallow linear echo of the plaque is accompanied by the rear sound shadow, the hard plaque is found, and if the low echo or the equal echo is found, the soft plaque is found.
1.2.2 diagnostic criteria of phlegm-blood stasis syndrome in TCM
The pattern of intermingled phlegm and blood stasis is diagnosed by referring to "macroscopic diagnostic criteria research of intermingled phlegm and blood stasis syndrome of coronary heart disease".
Macroscopic diagnosis standard (draft) for coronary heart disease with syndrome of intermingled phlegm and blood stasis
Note: compounding 2 main indexes, or 3 secondary indexes (applicable to blood stasis), or adding 2 secondary indexes into 1 main index, or respectively giving more than or equal to 6 points in the accumulated score, and then the phlegm-dampness or the blood stasis is established; the syndrome of intermingled phlegm and blood stasis can be diagnosed by the coexistence of phlegm-dampness and blood stasis.
1.3 inclusion criteria
(1) Arterial color hypermapping carotid plaque formation (soft or mixed plaque);
(2) age between 18 and 75 years;
(3) the syndrome differentiation of traditional Chinese medicine belongs to the syndrome of intermingled phlegm and blood stasis;
1.4 exclusion criteria
(1) Pregnant or lactating women;
(2) patients with complicated primary diseases of hematopoietic system, or serious liver and kidney dysfunction;
(3) disabled patients (e.g., legal disabilities such as physical disabilities, intellectual disabilities, dumb, deafness, blindness, and mental disorders);
(4) psychotic patients, or patients with a history of drug and alcohol abuse;
(5) people who cannot take simvastatin and people who have allergy (people who have allergy to more than 2 medicines or foods);
(6) patients who participated in other drug clinical trials within the last 1 month;
(7) patients suffering from other diseases affecting lipid metabolism.
1.5 abort criterion
(1) Serious safety problems are found in the test, such as patients with rapid disease deterioration, or patients with serious complications or adverse reactions;
(2) the test shows that the medicine has poor or even ineffective treatment effect, does not have the clinical value of continuing to carry out, or continues to carry out effective treatment which can delay the experimenter;
(3) when the experiment shows that the implementation of the scheme has great deviation or great errors exist in the preparation of the clinical test scheme, the accurate evaluation of the curative effect of the medicament is difficult to carry out.
2 protocol
Screening patients with the phlegm-blood stasis intermingled syndrome carotid arteriosclerosis, selecting a random, contrast, double-blind, single-simulation agent and excellent effect test research method, administering a simvastatin tablet and a depression-resolving, phlegm-eliminating and blood-stasis-removing placebo to a contrast group, administering a simvastatin tablet and a depression-resolving, phlegm-resolving and blood-stasis-removing granule to a treatment group, detecting carotid ultrasound, glycolipid metabolism and traditional Chinese medicine syndromes at the beginning and the end of the research, and observing the clinical effects of the depression-resolving, phlegm-eliminating and blood-stasis-removing prescription on the patients.
3 results of the experiment
3.1 comparison of the thickness of the medial carotid intima (c-IMT) before and after treatment in two groups of patients
Through the rank-sum test, the patients in two groups have no statistical difference between c-IMT groups before treatment (Z is-0.446, and P is 0.656), and the patients in two groups have comparability between the groups; patients in the control group had no statistical difference in c-IMT before and after treatment (Z-0.011, P-0.991); the c-IMT of the patients in the treatment group is obviously different before and after treatment (Z is-2.969, and P is 0.003), and is obviously reduced compared with that before treatment; there were no statistical differences between the c-IMT groups after treatment in both groups (Z ═ 1.250, P ═ 0.211). (see Table 1)
TABLE 1 c-IMT comparison (mm) [ M (max, min) ]before and after treatment of two groups of patients
Remarking: p < 0.01 compared to before treatment
3.2 plaque thickness comparison before and after treatment of two groups of patients
The plaque thickness before treatment of two groups of patients has no statistical difference (Z is-0.445, P is 0.656) through the rank-sum test, and the plaque thickness is comparable between the groups; patients in the control group had no statistical difference in plaque thickness before and after treatment (Z ═ 1.665, P ═ 0.096); the plaque thickness of the patients in the treatment group is obviously different before and after treatment (Z is-3.084, and P is 0.002), and is obviously reduced compared with that before treatment; there were no statistical differences between the plaque thickness groups after treatment in both groups of patients (Z ═ 0.966, P ═ 0.334). (see Table 2)
TABLE 2 comparison of plaque thickness (mm) [ M (max, min) ]before and after treatment for two groups of patients
Remarking: p < 0.01 compared to before treatment
3.3 comparison of glycolipid metabolism before and after treatment
Through the rank-sum test, the Triglyceride (TG), the Total Cholesterol (TC), the high-density lipoprotein (HDL-C), the low-density lipoprotein (LDL-C) and the fasting blood glucose (FPG) of two groups of patients have no statistical difference (P is more than 0.05), and the patients have comparability among the groups; the TG, TC and HDL-C, LDL-C of the control group patients are not statistically different before and after treatment (P is more than 0.05), and FPG is increased compared with that before treatment (Z is-2.300, and P is 0.021); the TC of the patients in the treatment group is reduced compared with that before treatment (Z-2.060 and P-0.039), HDL-C is increased compared with that before treatment (Z-2.219 and P-0.026), FPG is increased compared with that before treatment (Z-2.313 and P-0.021), TG and LDL-C have no statistical difference before and after treatment (P is more than 0.05); there were no statistical differences between TG, TC, LDL-C and FPG groups (P > 0.05) and significant differences between HDL-C groups (Z-2.837, P-0.005) after treatment in both groups of patients. (see Table 3)
TABLE 3 comparison of glycolipid metabolism (mmol/L) [ M (max, min) ]before and after treatment in both groups of patients
Remarking: compared with before treatment*P is less than 0.05, compared with the control group after treatment#P＜0.01
3.4 integral comparison of Chinese medicine syndrome before and after treatment
Through the rank-sum test, the traditional Chinese medicine syndrome scores of the two patients before treatment have no statistical difference (Z is-0.872, P is 0.383), and the traditional Chinese medicine syndrome scores are comparable among the patients; the traditional Chinese medicine syndrome integration before and after treatment of patients in a control group is obviously different (Z is-4.715, P is 0.000), and is improved compared with that before treatment; the traditional Chinese medicine syndrome integration before and after treatment of patients in a treatment group is obviously different (Z is-5.458, P is 0.000), and is improved compared with that before treatment; after the treatment of the two groups of patients, the traditional Chinese medicine syndrome score groups have obvious difference (Z is-2.946, and P is 0.003), which shows that the formula for resolving stagnation, reducing phlegm and removing blood stasis can effectively improve the traditional Chinese medicine syndrome of the patients. (see Table 4, FIG. 1)
TABLE 4 integral comparison of Chinese medicine syndrome before and after treatment [ M (max, min) ]for two groups of patients
Remarking: compared with before treatment***P is less than 0.001, compared with the control group after treatment#P＜0.01
3.5 comparison of the curative effects of the traditional Chinese medicines before and after treatment
The results show that the control group patients are effective for 7 cases (20.59%), effective for 18 cases (52.94%), ineffective for 9 cases (26.47%), the treatment group patients are effective for 16 cases (40.00%), effective for 21 cases (52.50%), ineffective for 3 cases (7.50%), and the treatment group is significantly better than the control group (Z is-2.390, P is 0.017). (see Table 5, FIG. 2)
TABLE 5 comparison of the therapeutic effects of the two groups of patients before and after treatment [ n (%) ]
3.6 comparison of effective rates of Chinese medicine before and after treatment
The result shows that the effective rate of the traditional Chinese medicine treatment in the control group is 73.5%, the effective rate of the traditional Chinese medicine treatment in the treatment group is 92.5%, and the treatment group is obviously superior to the control group (2 ═ 4.868, and P ═ 0.027). (see Table 6)
TABLE 6 comparison of effective rates of TCM treatment before and after treatment in two groups of patients [ n (%) ]
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and additions can be made without departing from the principle of the present invention, and these should also be considered as the protection scope of the present invention.
Claims (9)
1. The traditional Chinese medicine composition for treating carotid arteriosclerosis is characterized by comprising the following raw material medicines in parts by weight: 6-15 parts of rhizoma cyperi, 6-15 parts of ligusticum wallichii, 6-15 parts of rhizoma atractylodis, 6-15 parts of gardenia jasminoides, 6-15 parts of medicated leaven, 6-15 parts of hawthorn and 10-45 parts of corn stigma.
2. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight: 8-10 parts of rhizoma cyperi, 8-10 parts of ligusticum wallichii, 8-10 parts of rhizoma atractylodis, 8-10 parts of gardenia jasminoides, 8-10 parts of medicated leaven, 8-10 parts of hawthorn and 20-40 parts of corn stigma.
3. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight: 9 parts of rhizoma cyperi, 9 parts of ligusticum wallichii, 9 parts of rhizoma atractylodis, 9 parts of gardenia jasminoides, 9 parts of medicated leaven, 9 parts of hawthorn and 30 parts of corn stigma.
4. The Chinese medicinal composition according to any one of claims 1 to 3, which is prepared into a clinically acceptable medicinal preparation according to a conventional Chinese medicinal preparation method.
5. The traditional Chinese medicine composition of claim 4, wherein the pharmaceutical preparation is a granule, a powder, a capsule, a tablet, a mixture or an oral liquid.
6. Use of the Chinese medicinal composition of any one of claims 1-3 in the preparation of a medicament for the treatment of carotid arteriosclerosis.
7. The use of the Chinese medicinal composition of any one of claims 1-3 in the preparation of a medicament for the treatment of carotid arteriosclerosis due to intermingled phlegm and blood stasis.
8. A medicament for treating carotid arteriosclerosis, which is prepared by decocting the Chinese medicinal composition of claim 1 in water.
9. The medicament of claim 7, wherein the preparation method comprises:
(1) taking raw material medicines: rhizoma Cyperi, rhizoma Ligustici Chuanxiong, rhizoma Atractylodis, fructus Gardeniae, Massa Medicata Fermentata, fructus crataegi, and stigma Maydis, decocting with water over strong fire for 0.5-1.5 hr;
(2) decocting with slow fire for 20-40 min;
(3) and (4) leaching out juice, precipitating, taking clear liquid, and bottling for later use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011097703.2A CN112007119B (en) | 2020-10-14 | 2020-10-14 | Traditional Chinese medicine composition for treating carotid arteriosclerosis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011097703.2A CN112007119B (en) | 2020-10-14 | 2020-10-14 | Traditional Chinese medicine composition for treating carotid arteriosclerosis and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112007119A true CN112007119A (en) | 2020-12-01 |
| CN112007119B CN112007119B (en) | 2022-06-28 |
Family
ID=73528146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011097703.2A Active CN112007119B (en) | 2020-10-14 | 2020-10-14 | Traditional Chinese medicine composition for treating carotid arteriosclerosis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112007119B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116808162A (en) * | 2023-05-22 | 2023-09-29 | 上海中医药大学附属岳阳中西医结合医院 | Traditional Chinese medicine composition for preventing and treating ventricular premature contraction due to stagnation of gallbladder and phlegm and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090291154A1 (en) * | 2004-12-10 | 2009-11-26 | Tianjin Tasly Pharmaceutical Co., Ltd. | pharmaceutical composition for the treatment and/or prevention of hyperlipidemia, processes for producing the same and the use thereof |
| CN102423365A (en) * | 2011-12-03 | 2012-04-25 | 陈文实 | Traditional Chinese drug composition for treating carotid atherosclerosis plaque |
-
2020
- 2020-10-14 CN CN202011097703.2A patent/CN112007119B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090291154A1 (en) * | 2004-12-10 | 2009-11-26 | Tianjin Tasly Pharmaceutical Co., Ltd. | pharmaceutical composition for the treatment and/or prevention of hyperlipidemia, processes for producing the same and the use thereof |
| CN102423365A (en) * | 2011-12-03 | 2012-04-25 | 陈文实 | Traditional Chinese drug composition for treating carotid atherosclerosis plaque |
Non-Patent Citations (3)
| Title |
|---|
| 冯笑予等: "越鞠丸治疗痰浊阻遏型高脂血症患者疗效观察", 《黑龙江医学》 * |
| 孙素芹等: "越鞠丸对急性脑梗死伴抑郁患者的临床疗效及颈动脉斑块的影响", 《上海中医药大学学报》 * |
| 胡维勤: "《降脂怎么吃》", 30 April 2015, 安徽科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116808162A (en) * | 2023-05-22 | 2023-09-29 | 上海中医药大学附属岳阳中西医结合医院 | Traditional Chinese medicine composition for preventing and treating ventricular premature contraction due to stagnation of gallbladder and phlegm and application thereof |
| CN116808162B (en) * | 2023-05-22 | 2024-04-12 | 上海中医药大学附属岳阳中西医结合医院 | Traditional Chinese medicine composition for preventing and treating ventricular premature contraction due to stagnation of gallbladder and phlegm and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112007119B (en) | 2022-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100366280C (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN105031517A (en) | Dendrobium officinale healthcare tea capable of reducing blood fat, blood sugar, and blood pressure and preparation method thereof | |
| CN112007119B (en) | Traditional Chinese medicine composition for treating carotid arteriosclerosis and application thereof | |
| CN108567914B (en) | Traditional Chinese medicine preparation with sleep improving effect and preparation method and application thereof | |
| CN111195310A (en) | Traditional Chinese medicine composition for treating hyperlipidemia | |
| CN1369289A (en) | Chinese medicine for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN103977390A (en) | Method for preparing ginger-onion medicinal liquor composition and application thereof | |
| CN1814217B (en) | Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof | |
| CN110732004A (en) | A Chinese medicinal composition for treating cerebral ischemia | |
| CN109925469B (en) | Traditional Chinese medicine composition for treating liver-stagnation and spleen-deficiency type non-alcoholic fatty liver disease and application thereof | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| CN111166851B (en) | Traditional Chinese medicine for treating carotid plaque of hypertension patient | |
| CN111529593B (en) | Traditional Chinese medicine composition for preventing and treating phlegm-dampness urinary uric acid calculus and preparation method thereof | |
| CN108403803B (en) | Chinese medicinal compound preparation for preventing and treating cardiovascular complications of diabetes | |
| CN115501275B (en) | Traditional Chinese medicine composition for treating subdural hematoma and application thereof | |
| WO2004052382A1 (en) | A kind of chinese traditional medicine having efficacy of reducing blood-fat | |
| CN108079113A (en) | A kind of pharmaceutical composition for treating the postpartum deficiency of blood and preparation method thereof | |
| CN116270885B (en) | Traditional Chinese medicine composition for treating phlegm stagnation type coronary heart disease and application thereof | |
| CN106668601B (en) | Traditional Chinese medicine composition for treating cerebrovascular disease phlegm-heat syndrome and preparation method and application thereof | |
| CN113499411A (en) | Preparation method and application of traditional Chinese medicine composition for treating cerebral arterial thrombosis | |
| CN112546180A (en) | Health product and preparation method thereof | |
| CN100345561C (en) | Chinese medicinal preparation for treating gallstone and its preparation method | |
| CN104208571A (en) | Traditional Chinese medicinal composition for treating cardiovascular stenosis | |
| CN110755549A (en) | Traditional Chinese medicine composition for treating dyspepsia | |
| CN111888426A (en) | Medicine for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |